Skip to content
drillr.ai
Sign up

603087.SH

甘李药业

SSE · Healthcare · Medical - Instruments & Supplies · CN

CNY 65.47
−4.33%
Ask drillr

  • Aug 25, 2026, 09:09 UTC

    Ganli Pharmaceutical announced its 2026 first-half results: revenue of 2.223 billion yuan, up 7.56% year-on-year; net profit attributable to shareholders of 610 million yuan, up 1.01% year-on-year.

    Source:

  • Aug 24, 2026, 09:04 UTC

    Ganlee Pharmaceutical's subsidiary Ganlee Shandong received approval from China's National Medical Products Administration to conduct clinical trials for GZC8072 tablets for weight control.

    Source:

  • Aug 12, 2026, 13:50 UTC

    Gan & Lee Pharmaceuticals licensed its GLP-1RA biweekly formulation Bofanglutide to Italy's Menarini Group for European commercialization in 39 countries, receiving an upfront payment of 62 million euros and potential milestone payments of 664 million euros.

    Source:

  • Aug 9, 2026, 17:27 UTC

    Ganli Pharmaceutical presented 3 self-developed innovative formulations, including Bofanglutide, GZR4 and GZR102, at the 86th American Diabetes Association Scientific Sessions and released the latest clinical research data.

    Source:

  • Aug 6, 2026, 09:53 UTC

    Seven directors and senior executives of Gan & Lee Pharmaceuticals plan to reduce their holdings by a total of no more than 840,000 shares through centralized bidding transactions during the period from August 31 to November 30, 2026, accounting for 0.02% of the company's total share capital, for the purpose of repaying personal debts.

    Source:

  • Jul 9, 2026, 08:59 UTC

    Gan & Lee Pharmaceuticals received a drug registration certificate from the Honduras National Drug Regulatory Authority for its insulin glargine injection (prefilled pen) under the brand name VITAGLAR®.

    Source: